Retirement Systems of Alabama Buys New Stake in Cencora, Inc. $COR

Retirement Systems of Alabama bought a new stake in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, Holdings Channel reports. The firm bought 41,358 shares of the company’s stock, valued at approximately $12,926,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. First Citizens Bank & Trust Co. increased its holdings in shares of Cencora by 5.5% during the third quarter. First Citizens Bank & Trust Co. now owns 761 shares of the company’s stock valued at $238,000 after purchasing an additional 40 shares during the period. Sawgrass Asset Management LLC increased its stake in Cencora by 6.1% during the 3rd quarter. Sawgrass Asset Management LLC now owns 4,592 shares of the company’s stock valued at $1,435,000 after buying an additional 264 shares during the period. CIBC Asset Management Inc raised its position in shares of Cencora by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 66,201 shares of the company’s stock worth $20,678,000 after buying an additional 2,316 shares in the last quarter. TFR Capital LLC. raised its position in shares of Cencora by 1.4% during the 3rd quarter. TFR Capital LLC. now owns 5,907 shares of the company’s stock worth $1,846,000 after buying an additional 79 shares in the last quarter. Finally, Sagespring Wealth Partners LLC lifted its stake in shares of Cencora by 11.7% in the 3rd quarter. Sagespring Wealth Partners LLC now owns 2,286 shares of the company’s stock worth $715,000 after acquiring an additional 240 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $356.15 on Wednesday. The company has a market capitalization of $69.09 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The stock has a fifty day moving average of $348.17 and a 200-day moving average of $323.06. Cencora, Inc. has a one year low of $237.71 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the firm posted $3.34 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 30.19%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on COR shares. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company boosted their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. TD Cowen upped their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $393.08.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 20,316 shares of company stock valued at $7,151,265 over the last ninety days. Corporate insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.